|
🐜
|
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
10 auth.
T. Seeger,
P. Seymour,
Anne W. Schmidt,
S. Zorn,
D. Schulz,
L. Lebel,
...
S. Mclean,
V. Guanowsky,
H. Howard,
J. Lowe
|
8 |
1995 |
8
🐜
|
|
🐜
|
Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor
18 auth.
M. Iwata,
Kristie T. Ota,
Xiao-Yuan Li,
Fumika Sakaue,
Nanxin Li,
S. Dutheil,
M. Banasr,
Vanja Duric,
Takehiko Yamanashi,
K. Kaneko,
...
K. Rasmussen,
A. Glasebrook,
A. Koester,
D. Song,
K. A. Jones,
S. Zorn,
G. Smagin,
R. Duman
|
8 |
2016 |
8
🐜
|
|
🐢
|
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Anne W. Schmidt,
L. Lebel,
H. Howard,
S. Zorn
|
8 |
2001 |
8
🐢
|
|
🐢
|
Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.
H. Rollema,
Y. Lu,
Anne W. Schmidt,
S. Zorn
|
7 |
1997 |
7
🐢
|
|
🐢
|
5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex
H. Rollema,
Yi Lu,
Anne W. Schmidt,
J. Sprouse,
S. Zorn
|
7 |
2000 |
7
🐢
|
|
🦁
|
Clozapine is a potent and selective muscarinic M4 receptor agonist.
S. Zorn,
Shawn B. Jones,
K. Ward,
D. Liston
|
7 |
1994 |
7
🦁
|
|
🐜
|
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
142 auth.
Renzo Mancuso,
Gemma L. Fryatt,
Madeleine Cleal,
J. Obst,
E. Pipi,
Jimena Monzón-Sandoval,
Elena Ribe,
L. Winchester,
C. Webber,
Alejo J. Nevado,
T. Jacobs,
N. Austin,
C. Theunis,
Karolien Grauwen,
Eva Daniela Ruiz,
...
A. Mudher,
Marta Vicente-Rodríguez,
Christine A Parker,
C. Simmons,
Diana Cash,
Jill C Richardson,
E. Bullmore,
Junaid Bhatti,
Samuel J. Chamberlain,
M. Correia,
Anna L. Crofts,
A. Dickinson,
A. Foster,
M. Kitzbichler,
Clare Knight,
M. Lynall,
Christina Maurice,
Ciara O’Donnell,
L. Pointon,
P. Hyslop,
L. Turner,
P. Vértes,
B. Widmer,
G. Williams,
B. Morgan,
C. Leckey,
A. Morgan,
C. O’Hagan,
Samuel Touchard,
J. Cavanagh,
Catherine Deith,
Scott J. Farmer,
J. Mcclean,
A. McColl,
Andrew McPherson,
Paul Scouller,
Murray Sutherland,
H. Boddeke,
Jill C Richardson,
Shahid Khan,
Phil Murphy,
Christine A Parker,
Jai Patel,
Declan N C Jones,
P. de Boer,
J. Kemp,
W. Drevets,
J. Nye,
G. Wittenberg,
J. Isaac,
A. Bhattacharya,
N. Carruthers,
H. Kolb,
C. Pariante,
F. Turkheimer,
G. Barker,
H. Byrom,
Diana Cash,
A. Cattaneo,
Antony D. Gee,
C. Hastings,
N. Mariani,
A. McLaughlin,
V. Mondelli,
M. Nettis,
N. Nikkheslat,
K. Randall,
Hannah Sheridan,
C. Simmons,
Nisha Singh,
V. V. Loo,
Marta Vicente-Rodríguez,
Tobias C. Wood,
C. Worrell,
Z. Zajkowska,
N. Plath,
J. Egebjerg,
H. Eriksson,
F. Gastambide,
Karen H. Adams,
R. Jeggo,
Christian Thomsen,
J. Pederson,
B. Campbell,
T. Möller,
Bob Nelson,
S. Zorn,
Jason O’Connor,
M. Attenburrow,
A. Baird,
Jithen Benjamin,
S. Clare,
Philip A. Cowen,
I. Huang,
Sam Hurley,
Helen Jones,
Simon Lovestone,
Francisca Mada,
A. Nevado-Holgado,
Akintayo Oladejo,
Elena Ribe,
Katy Smith,
Anviti Vyas,
Zoe Hughes,
R. Balice-Gordon,
J. Duerr,
Justin R. Piro,
J. Sporn,
V. Hugh Perry (PI,
Madeleine Cleal,
Gemma L. Fryatt,
Diego Gomez-Nicola,
Renzo Mancuso,
Richard Reynolds,
N. Harrison,
M. Cercignani,
Charlotte L Clarke,
E. Hoskins,
C. Kohn,
Rosemary Murray,
Lauren Wilcock,
Dominika Wlazły,
H. Mount,
Declan N C Jones,
Simon Lovestone,
Diego Gomez-Nicola,
V. Perry
|
7 |
2019 |
7
🐜
|
|
🐜
|
Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration
35 auth.
J. Ryu,
Victoria A. Rafalski,
A. Meyer‐Franke,
Ryan A. Adams,
S. Poda,
Pamela E. Rios Coronado,
L. Pedersen,
Veena Menon,
K. M. Baeten,
Shoana L. Sikorski,
C. Bedard,
K. Hanspers,
Sophia Bardehle,
Andrew S. Mendiola,
Dimitrios Davalos,
...
Michael R. Machado,
Justin P. Chan,
I. Plastira,
Mark A. Petersen,
S. Pfaff,
K. Ang,
K. Hallenbeck,
Catriona A. Syme,
H. Hakozaki,
Mark Ellisman,
R. Swanson,
S. Zamvil,
M. Arkin,
S. Zorn,
Alexander R. Pico,
L. Mucke,
Stephen Freedman,
J. Stavenhagen,
R. Nelson,
K. Akassoglou
|
7 |
2018 |
7
🐜
|
|
🐬
|
Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
Duncan Ge,
S. Zorn,
JA Lieberman
|
6 |
1999 |
6
🐬
|
|
🐜
|
The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst.
10 auth.
J. Lowe,
S. Drozda,
R. Snider,
K. P. Longo,
S. Zorn,
J. Morrone,
...
E. Jackson,
S. Mclean,
D. Bryce,
J. Bordner
|
6 |
1992 |
6
🐜
|
|
🐢
|
Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition
R. Mansbach,
Elizabeth W. Brooks,
M. Sanner,
S. Zorn
|
6 |
1998 |
6
🐢
|
